Penny Foskaris is a Functional Nutrition Specialist and founder of Foskaris Wellness, a private longevity practice. She is a member of the American Academy of Anti-Aging Medicine and has worked with thousands of women navigating hormonal transitions, metabolic slowdowns, and the gap between how they feel and how they know they should feel.
The conversation about women’s hormones has been broken for decades. Conventional medicine either dismisses the symptoms as stress or aging, or reaches for a one-size prescription without looking at the full picture. Functional and integrative medicine often overcorrects into complicated protocols that are expensive, time-consuming, and not always grounded in data.
What actually works is simpler and more targeted: get the right labs, interpret them correctly, and build a protocol around what your biology is actually doing, not what it statistically should be doing at your age.
Why Hormones Start Shifting Before You Expect Them To
The hormonal decline that most women call menopause actually begins 10 to 15 years earlier, and the effects are measurable long before a single missed period.
Progesterone is typically the first hormone to drop, often in the mid-30s. Progesterone is the calming, sleep-promoting hormone. When it declines, sleep becomes lighter and less restorative, anxiety increases, and cycles become irregular. Most women at this stage are told their labs are “normal” because their estrogen is still adequate. But progesterone to estrogen ratio matters. A relative estrogen dominance, where estrogen is not elevated but progesterone has dropped, produces a specific cluster of symptoms that gets missed constantly.
Testosterone, which women produce in smaller amounts than men but rely on for energy, libido, cognitive clarity, and muscle maintenance, declines steadily from the late 20s. By 40, many women have lost a significant fraction of their peak testosterone. By 50, the loss is substantial. This matters because testosterone is the hormone that makes you feel driven, capable, and resilient. Its absence is felt as flatness, low motivation, and a body that no longer responds to training the way it used to.
Estrogen becomes the variable hormone in perimenopause. It does not simply decline in a straight line. It oscillates, sometimes surging higher than normal before dropping. These fluctuations drive hot flashes, mood swings, heavy periods, and the bone and cardiovascular changes that accelerate in the years around menopause.
Understanding this timeline matters because the window for intervention is not at menopause. It is years before.
What Standard Labs Miss
The most common reason hormone problems go unaddressed is not a lack of testing. It is a lack of the right testing, interpreted in the right context.
Standard bloodwork ordered at an annual physical typically includes TSH for thyroid and occasionally estradiol. It rarely includes free testosterone, DHEA-S, progesterone, or a full thyroid panel with free T3 and free T4. When these markers are not measured, the clinical picture is incomplete.
Even when hormone labs are ordered, reference ranges can be misleading. The “normal” range for testosterone in women, for example, spans from approximately 15 to 70 ng/dL depending on the lab. A woman at 16 ng/dL is technically in range. But if her symptoms are consistent with testosterone deficiency, and her free testosterone is low, being “in range” on paper does not mean she is functioning optimally.
The same applies to thyroid. TSH can be technically normal while free T3, the active thyroid hormone, is low. Women with low free T3 experience fatigue, cold intolerance, weight gain, and hair thinning despite having a TSH that their provider considers acceptable.
The labs I run on every new LongevityRX client include estradiol, progesterone, total and free testosterone, DHEA-S, SHBG, FSH, LH, TSH, free T3, free T4, fasting insulin, fasting glucose, and a full metabolic panel. These are interpreted together, in the context of symptoms, cycle timing, and health history. Not as isolated numbers compared against a population average.
The Four Hormonal Drivers of Female Metabolic Decline
Most women who struggle with weight, fatigue, or body composition after 35 are not failing at diet or exercise. They are fighting four simultaneous hormonal shifts that work against each other.
Estrogen and insulin sensitivity. Estrogen promotes insulin sensitivity in muscle tissue. When estrogen declines, insulin resistance increases, particularly in the abdominal region. Fat storage shifts from the hips and thighs, where estrogen directs it in younger women, to the abdomen. This is not a willpower problem. It is a metabolic consequence of estrogen loss.
Progesterone and cortisol. Progesterone has a calming, anti-anxiety effect partly because it interacts with GABA receptors in the brain. When progesterone drops, the nervous system becomes more reactive to stress. Cortisol output increases. Elevated cortisol drives fat storage, muscle breakdown, and sleep disruption. This creates a cycle: low progesterone leads to poor sleep and high cortisol, which makes fat loss harder, which creates more stress, which drives more cortisol.
Testosterone and muscle mass. Testosterone is the primary anabolic hormone in both men and women. It supports muscle protein synthesis and maintains the muscle mass that drives basal metabolic rate. When testosterone is low, the body loses muscle mass progressively, even in women who train consistently. Less muscle means a slower metabolism and a more pronounced body composition shift toward fat.
Thyroid and metabolic rate. Hypothyroidism and subclinical thyroid dysfunction are significantly more common in women than men and increase in prevalence with age. Even mild thyroid underfunction reduces the metabolic rate, impairs fat metabolism, contributes to fatigue, and makes every other hormonal intervention less effective.
Addressing one of these in isolation produces limited results. Addressing all four, in the right sequence and with ongoing lab monitoring, is what actually moves the needle.
What Hormone Optimization Actually Looks Like
A hormone optimization protocol is not a prescription. It is a process. It begins with data, adjusts based on response, and evolves as your biology changes.
The first step is a comprehensive baseline. Labs, a detailed health history, sleep quality, stress markers, body composition, and symptom inventory. This baseline is what all future decisions are referenced against.
From there, the protocol is built around the specific gaps. If progesterone is low relative to estrogen, progesterone support is prioritized. If testosterone is low, testosterone optimization is addressed. If thyroid markers show subclinical dysfunction, thyroid support is considered. These are not automatic interventions applied to everyone. They are clinical decisions made based on your numbers and your symptoms together.
For women who are candidates for hormone therapy, bioidentical hormones are typically preferred in the LongevityRX protocol. Bioidentical hormones have the same molecular structure as the hormones your body produces. They are typically better tolerated and more precisely dosed than synthetic alternatives.
Nutrition, sleep, and stress management are built into the protocol alongside any hormonal interventions. Hormone therapy on top of a high-sugar diet and chronic sleep deprivation will not produce the results that hormone therapy combined with targeted nutrition and recovery optimization will. These elements are not separate tracks. They are integrated.
Progress is tracked with follow-up labs at 6 to 12 weeks, then adjusted accordingly. The goal is not to hit a specific number on a lab report. The goal is for you to feel and perform at your best, with lab data confirming that the biology supports it.
The Relationship Between Hormones and Longevity
Hormone optimization is not just about feeling better in the short term. It is one of the most significant levers for long-term health and disease prevention available to women.
Estrogen has protective effects on the cardiovascular system, the brain, and bone density. The 10-year period following menopause is when women’s cardiovascular disease risk rises sharply, catching up to and eventually exceeding men’s risk. Bone density declines at its fastest rate in the first 5 to 7 years after menopause. Cognitive decline is associated with estrogen loss.
This does not mean every woman should be on hormone therapy indefinitely. It means that decisions about hormone optimization should factor in long-term health protection, not just current symptom relief.
DHEA, the precursor hormone from which both estrogen and testosterone are synthesized, also declines with age and has been studied for its role in immune function, bone health, and cardiovascular protection. Optimizing DHEA levels is a component of the longevity protocol for many women, separate from direct sex hormone replacement.
The window for maximum benefit from hormone therapy is generally within 10 years of menopause onset, sometimes called the critical window hypothesis. Women who begin hormone optimization earlier in the perimenopausal transition tend to maintain better bone density, cognitive function, and cardiovascular markers long term than those who delay.
What to Do If You Recognize Yourself in This
If the pattern described here matches your experience, the next step is not another elimination diet or a new supplement stack. The next step is data.
A comprehensive hormone panel, interpreted by someone who understands functional ranges and the relationship between hormones rather than just individual values, will tell you more about what is actually happening in your body than years of trial and error.
The LongevityRX for Women program begins with exactly that: advanced lab testing, a personalized protocol built around your biology, and ongoing monitoring to track and adjust as your body responds. If you are ready to stop guessing and start working with your biology, inquire about working together.
